June 22, 2020 09:44 AM EDT

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset

John Carroll

Editor & Founder

Roche has posted some new, early-stage data on its anti-TIGIT drug tiragolumab in solid tumors that are being studied for fresh signs on the closely …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Updated: Bay Area biotech VC to shut down 15 months after launch, sources say, after key investor pulls out

Major FDA staff cuts would slow drug reviews, experts say

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

Roche heads to FDA with Gazyva results in a form of lupus

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Bristol Myers prunes pipeline amid new round of cost cuts

Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset